Another step towards sharpening molecular subclassification of chordoma: new genomic subtypes identified based on copy number alterations, correlating with known immune and methylation based clusters sciencedirect.com/science/ar…

#ASCO26 Targeting EGFR in #chordoma: Abstract 11527, @APConley77 #sarcoma - IIT of cetuximab in met/unresect chordoma - n = 25 evaluable - 48% (12/25) with size reduction, 8% (2/25) meeting criteria for PR. SD in remainder (92%, 23/25) - Prelim mPFS/OS 9.9/38.8mo

Turns out there’s a lot of interest in a fast and free experimental benchmark of AI small molecule discovery capabilities. 👀 As a result we’re announcing a few updates to the TBXT Challenge: 1. June 1, 2026 is the last date we will accept new entrants. To register and reserve testing slots, please email us at TBXTchallenge@chordoma.org by June 1st. (Or if you know anyone who might be interested please encourage them to get in by then) 2. To participate in the Challenge, a competitor’s first batch of compounds must be received by CF Labs by September 1, 2026. 3. Competitors with compounds found to have Kd <10 μM in their first or second batch submitted to the Challenge may step out of the Challenge and perform hit optimization under a sponsored research agreement (SRA) with CF Labs. In this scenario, the competitor has the option to fund testing of up to two rounds of 60 compounds (up to a total of 120 compounds) in the SPR assay. If a two-fold increase in potency is achieved after these two rounds, up to two additional rounds of 60 compounds may be tested. After completing testing under an SRA, a competitor may re-enter the Challenge by submitting the remainder of their 96 allotted compounds for evaluation within the Challenge. Please reach out with any questions and good luck to those competing!

Awesome to see the @adaptyvbio protein design competition bear fruit. Great example of the power of competitions with wet lab validation to surface computational solutions to molecular design problems. This quote from the winning team @BioMandrake stood out: “We’re a fairly young company that’s just started out, and are setting up our wet lab as we speak. This competition was a great way for us to validate some of our hypotheses and see how they stand against actual wet lab results. The Adaptyv competition was the cleanest version of that benchmark we’d seen.” For anyone looking for a similar opportunity to benchmark small molecule design against a difficult target, our TBXT Challenge is here for you tbxtchallenge.org/

Congratulations to @XChemInc for an excellent AACR poster on their DEL data-driven discovery of TBXT ligands! aacrjournals.org/cancerres/a…